CalciMedica (CALC)
Market Price (4/12/2026): $0.6202 | Market Cap: $9.8 MilSector: Health Care | Industry: Biotechnology
CalciMedica (CALC)
Market Price (4/12/2026): $0.6202Market Cap: $9.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -154% | Penny stockMkt Price is 0.6 Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -23 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -305% High stock price volatilityVol 12M is 134% Key risksCALC key risks include [1] the potential failure of pivotal clinical trials for its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -34% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -154% |
| Penny stockMkt Price is 0.6 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -23 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -305% |
| High stock price volatilityVol 12M is 134% |
| Key risksCALC key risks include [1] the potential failure of pivotal clinical trials for its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
CalciMedica (CALC) stock has lost about 90% since 12/31/2025 because of the following key factors:
1. Discontinuation of the Phase 2 KOURAGE Trial for Acute Kidney Injury (AKI) led to a significant stock price plunge.
In January 2026, CalciMedica announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure. This decision followed a recommendation from the Independent Data Monitoring Committee (IDMC) due to a safety concern involving a mortality imbalance, which prompted a reevaluation of the study design, particularly patient enrollment criteria. Despite no deaths being attributed to the study drug, this news caused CalciMedica's stock to plummet 76% on January 28, 2026, with an additional 4% decline in after-hours trading.
2. The company reported a substantial earnings miss and a widening net loss for Q4 2025.
On March 3, 2026, CalciMedica reported its Q4 2025 financial results, with an earnings per share (EPS) of -$0.69, missing analysts' consensus estimate of -$0.47 by 46.81%. For the full year ended December 31, 2025, the net loss significantly widened to $29.6 million, or $1.97 per basic and diluted share, compared to a net loss of $13.7 million, or $1.22 per share, in 2024. This increased loss was primarily driven by non-cash fair value adjustments to financial instruments and higher interest expenses.
Show more
1. Discontinuation of the Phase 2 KOURAGE Trial for Acute Kidney Injury (AKI) led to a significant stock price plunge.
In January 2026, CalciMedica announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure. This decision followed a recommendation from the Independent Data Monitoring Committee (IDMC) due to a safety concern involving a mortality imbalance, which prompted a reevaluation of the study design, particularly patient enrollment criteria. Despite no deaths being attributed to the study drug, this news caused CalciMedica's stock to plummet 76% on January 28, 2026, with an additional 4% decline in after-hours trading.
2. The company reported a substantial earnings miss and a widening net loss for Q4 2025.
On March 3, 2026, CalciMedica reported its Q4 2025 financial results, with an earnings per share (EPS) of -$0.69, missing analysts' consensus estimate of -$0.47 by 46.81%. For the full year ended December 31, 2025, the net loss significantly widened to $29.6 million, or $1.97 per basic and diluted share, compared to a net loss of $13.7 million, or $1.22 per share, in 2024. This increased loss was primarily driven by non-cash fair value adjustments to financial instruments and higher interest expenses.
Show more
Stock Movement Drivers
Fundamental Drivers
The -90.6% change in CALC stock from 12/31/2025 to 4/11/2026 was primarily driven by a -4.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.59 | 0.62 | -90.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 15 | 16 | -4.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| CALC | -90.6% | |
| Market (SPY) | -5.4% | -4.8% |
| Sector (XLV) | -4.8% | 1.9% |
Fundamental Drivers
The -79.9% change in CALC stock from 9/30/2025 to 4/11/2026 was primarily driven by a -5.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.08 | 0.62 | -79.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 15 | 16 | -5.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| CALC | -79.9% | |
| Market (SPY) | -2.9% | 6.0% |
| Sector (XLV) | 6.3% | 4.7% |
Fundamental Drivers
The -67.7% change in CALC stock from 3/31/2025 to 4/11/2026 was primarily driven by a -18.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.91 | 0.62 | -67.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 13 | 16 | -18.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| CALC | -67.7% | |
| Market (SPY) | 16.3% | 3.4% |
| Sector (XLV) | 2.3% | 7.5% |
Fundamental Drivers
The -87.6% change in CALC stock from 3/31/2023 to 4/11/2026 was primarily driven by a -99.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312023 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.00 | 0.62 | -87.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 16 | -99.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/11/2026| Return | Correlation | |
|---|---|---|
| CALC | -87.6% | |
| Market (SPY) | 63.3% | 3.3% |
| Sector (XLV) | 19.1% | 6.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CALC Return | -94% | -73% | -59% | 24% | 86% | -90% | -100% |
| Peers Return | -40% | -38% | 2% | 83% | 110% | 16% | 70% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| CALC Win Rate | 25% | 25% | 17% | 42% | 42% | 50% | |
| Peers Win Rate | 45% | 42% | 58% | 45% | 48% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CALC Max Drawdown | -94% | -75% | -75% | -6% | -60% | -92% | |
| Peers Max Drawdown | -51% | -61% | -52% | -19% | -50% | -24% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PRAX, EQ, KNSA, OMER, APLS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | CALC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -95.0% | -25.4% |
| % Gain to Breakeven | 1888.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to PRAX, EQ, KNSA, OMER, APLS
In The Past
CalciMedica's stock fell -95.0% during the 2022 Inflation Shock from a high on 1/22/2021. A -95.0% loss requires a 1888.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About CalciMedica (CALC)
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC, Graybug Vision, Inc. in 2016 and changed its name to CalciMedica, Inc. in 2023. CalciMedica, Inc. was incorporated in 2011 and is based in Redwood City, California.
AI Analysis | Feedback
1. The Regeneron of long-lasting eye disease treatments.
AI Analysis | Feedback
- GB-102: An intravitreal injection formulation of sunitinib being developed for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
- GB-401: An intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor designed to treat primary open-angle glaucoma.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
A. Rachel Leheny, Ph.D. Chief Executive Officer
Dr. Leheny has served as Chief Executive Officer since September 2019 (or since 2020) and brings over 30 years of experience in the life sciences industry. Her background includes roles as a scientist, venture capital investor, and investment banking research analyst.
Stephen Bardin, MBA Chief Financial Officer
Mr. Bardin was appointed Chief Financial Officer on November 7, 2024. He possesses extensive expertise in capital raising, corporate development, and strategic finance. Prior to joining CalciMedica, he served as CFO of atai Life Sciences, where he was integral to investor relations, business development, capital allocation, and financial operations. Before atai, Mr. Bardin spent nearly three years at BridgeBio Pharma, Inc., where he oversaw diverse finance activities and helped raise over $2 billion through various financing transactions. He also held roles in finance, operations, and corporate development at Myovant Sciences and began his career consulting for life sciences companies at the Boston Consulting Group.
Michael J. Dunn, MBA President and Chief Operating Officer
Eric W. Roberts Chief Business Officer
Mr. Roberts has 30 years of experience in the finance, investment, and life sciences industries, having completed numerous financings and merger transactions. He co-founded the investment firm Valence Life Sciences in 2012 and previously co-founded and managed the Caxton Advantage Life Sciences Fund starting in 2005. He has also served on the boards of several public and private life science companies.
Kenneth A. Stauderman, Ph.D. Chief Scientific Officer
AI Analysis | Feedback
The key risks to CalciMedica's business are:- Clinical Trial and Regulatory Approval Risk: CalciMedica is a clinical-stage biopharmaceutical company, and its success is entirely dependent on the successful outcome of its ongoing and future clinical trials for product candidates like GB-102 and GB-401. There is significant risk that these candidates may fail to demonstrate efficacy, safety, or achieve desired endpoints in their respective clinical phases (Phase I/IIa, IIb), or may not receive regulatory approval from health authorities, even if clinical data is positive. Failure at any stage of development would significantly impair the company's ability to generate revenue and sustain operations.
- Product Development and Commercialization Risk (Limited Pipeline): The company's future hinges heavily on the successful development, regulatory approval, and subsequent commercialization of a very limited number of product candidates, primarily GB-102. If GB-102 fails in clinical trials, or if it encounters significant challenges in securing market adoption, pricing, or competition upon potential approval, CalciMedica has limited other late-stage candidates to rely upon, with GB-401 being in an earlier stage of development. This concentration of risk on a few assets makes the company vulnerable to setbacks with any of its lead programs.
- Funding and Financing Risk: As a clinical-stage company without revenue from commercialized products, CalciMedica relies on external funding to finance its extensive and costly research and development activities, particularly clinical trials. There is a risk that the company may not be able to raise sufficient additional capital on favorable terms, or at all, in the future. A lack of adequate funding could force delays, reductions, or even termination of its development programs, ultimately impacting its ability to bring products to market.
AI Analysis | Feedback
The emergence and advancement of gene therapies for retinal and optic nerve diseases pose a clear emerging threat. These therapies aim to provide single-administration, durable treatments by introducing genetic material to produce therapeutic proteins or correct genetic defects. If successful in common indications such as wet age-related macular degeneration, diabetic macular edema, or glaucoma, these one-time treatments could significantly disrupt the market for CalciMedica's lead product candidates like GB-102 and GB-401, which are long-acting formulations that still require repeated injections, by offering a superior convenience profile that potentially eliminates the need for recurrent administrations entirely.
AI Analysis | Feedback
The addressable markets for CalciMedica's main products are as follows:
- Wet Age-Related Macular Degeneration (Wet AMD): The market size for Wet AMD in the top 7 markets (US, EU4, UK, and Japan) was valued at USD 9,528.8 million in 2024 and is projected to reach USD 18,317.5 million by 2035. In the United States alone, the Wet AMD market was approximately USD 2,599 million in 2023. Globally, the wet AMD market size was USD 9.4 billion in 2024. Another source indicates the global wet age-related macular degeneration market size was USD 10.6 billion in 2025 and is projected to reach USD 16.7 billion by 2032.
- Diabetic Macular Edema (DME): The global diabetic macular edema market size was estimated at USD 5.4 billion in 2023 and is expected to reach USD 7.5 billion by 2034. Another report valued the global DME market at USD 3.33 billion in 2024, projected to reach USD 4.34 billion by 2032. Across the top 7 markets (US, EU4, UK, and Japan), the DME market reached USD 5.6 billion in 2024 and is expected to reach USD 7.8 billion by 2035. The United States accounts for approximately 60% of the Diabetic Macular Edema market size in the 7MM in 2023.
- Diabetic Retinopathy (DR): The global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to grow to approximately USD 18.93 billion by 2035. North America held the largest revenue share of 37.8% in the global diabetic retinopathy market in 2024. The U.S. diabetic retinopathy market was valued at USD 3.02 billion in 2024 and is expected to reach USD 4.92 billion by 2032.
- Primary Open-Angle Glaucoma (POAG): The open-angle glaucoma market across the top 7 markets (US, EU4, UK, and Japan) reached USD 6.0 billion in 2024 and is projected to reach USD 8.7 billion by 2035. The global glaucoma market size, which includes open-angle glaucoma as the dominant segment, was estimated at USD 8.03 billion in 2022 and is projected to reach USD 11.52 billion by 2030. The global glaucoma treatment market size was valued at USD 6.6 billion in 2024 and is expected to grow to USD 10.5 billion by 2034. The open-angle glaucoma segment of the global glaucoma treatment market was valued at USD 5.4 billion in 2024. North America accounted for the largest revenue share of 38.60% in the global glaucoma market in 2022. The U.S. glaucoma market size was approximately USD 2.45 billion in 2024 and is projected to reach around USD 3.96 billion by 2034.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for CalciMedica (CALC) over the next 2-3 years:
- Advancement and Potential Commercialization of Auxora for Acute Pancreatitis (AP): CalciMedica is actively progressing Auxora, its lead CRAC channel inhibitor, toward a pivotal program for acute pancreatitis (AP). The company anticipates finalizing the design of this pivotal program in the first half of 2026. Acute pancreatitis represents a significant unmet medical need, with approximately 300,000 hospitalizations annually in the U.S.. Successful completion of pivotal trials, regulatory approval, and subsequent commercialization would be a primary driver of future revenue.
- Potential Future Development of Auxora for Acute Kidney Injury (AKI): Although CalciMedica discontinued the Phase 2 KOURAGE trial for acute kidney injury (AKI) in January 2026 due to a mortality imbalance, internal and external reviews did not identify evidence of drug-related toxicity with Auxora. The company plans to engage in discussions with the FDA in the second quarter of 2026 regarding the KOURAGE data and potential future development pathways for Auxora in AKI. Refined trial designs and successful re-entry into clinical development for this indication could also contribute to future revenue.
- Advancement of CM5480 for Pulmonary Arterial Hypertension (PAH): CalciMedica is also developing CM5480, a second CRAC channel inhibitor, as a potential therapy for pulmonary arterial hypertension (PAH). Preclinical data supporting its potential has been published, and an Investigational New Drug (IND) submission for CM5480 is anticipated in 2027. Successful clinical development and eventual commercialization of CM5480 would establish a new revenue stream for the company.
- Strategic Partnerships and Licensing Agreements: As a clinical-stage biopharmaceutical company, CalciMedica may pursue strategic partnerships or licensing agreements for its pipeline candidates, Auxora and CM5480. Such collaborations could provide upfront payments, milestone payments, and royalties, contributing to revenue growth and supporting the continued development and commercialization of its therapies.
AI Analysis | Feedback
Share Issuance
- Issued and outstanding common stock increased from 13,481,917 shares at December 31, 2024, to 15,437,410 shares at December 31, 2025.
- In late 2022, a private placement involved investors agreeing to purchase an aggregate of $10.3 million of CalciMedica common stock.
- On March 3, 2026, CalciMedica filed a shelf registration to offer up to $125 million in various securities, including common stock, for general corporate purposes.
Inbound Investments
- CalciMedica held cash, cash equivalents, and short-term investments of $13.0 million as of December 31, 2025.
- The company's cash position, including cash, cash equivalents, and short-term investments, was $24.6 million as of March 31, 2025.
- As of June 30, 2025, cash, cash equivalents, and short-term investments totaled $18.0 million.
Capital Expenditures
- CalciMedica invested $6K in capital expenditures in Q4 2025.
Trade Ideas
Select ideas related to CALC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 26.14 |
| Mkt Cap | 2.2 |
| Rev LTM | 0 |
| Op Inc LTM | -23 |
| FCF LTM | -22 |
| FCF 3Y Avg | -43 |
| CFO LTM | -22 |
| CFO 3Y Avg | -43 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -35.8% |
| Rev Chg 3Y Avg | 46.5% |
| Rev Chg Q | -53.0% |
| QoQ Delta Rev Chg LTM | -50.6% |
| Op Mgn LTM | 8.5% |
| Op Mgn 3Y Avg | -25.8% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | 12.4% |
| CFO/Rev 3Y Avg | -20.9% |
| FCF/Rev LTM | 12.3% |
| FCF/Rev 3Y Avg | -21.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.2 |
| P/S | 5.2 |
| P/EBIT | -2.5 |
| P/E | -2.6 |
| P/CFO | -2.7 |
| Total Yield | -2.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -13.2% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.4% |
| 3M Rtn | 10.0% |
| 6M Rtn | 48.4% |
| 12M Rtn | 126.9% |
| 3Y Rtn | 124.0% |
| 1M Excs Rtn | -1.6% |
| 3M Excs Rtn | 11.6% |
| 6M Excs Rtn | 42.4% |
| 12M Excs Rtn | 93.1% |
| 3Y Excs Rtn | 73.1% |
Price Behavior
Price Behavior
| Market Price | $0.62 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 09/25/2020 | |
| Distance from 52W High | -90.8% | |
| 50 Days | 200 Days | |
| DMA Price | $0.65 | $2.84 |
| DMA Trend | down | down |
| Distance from DMA | -5.0% | -78.2% |
| 3M | 1YR | |
| Volatility | 199.2% | 134.4% |
| Downside Capture | 4.19 | 1.28 |
| Upside Capture | -422.45 | 68.81 |
| Correlation (SPY) | -2.1% | 7.5% |
CALC Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.33 | 0.06 | -1.04 | 0.76 | 0.23 | 0.24 |
| Up Beta | 14.88 | 6.46 | 5.17 | 5.38 | -0.29 | -0.23 |
| Down Beta | 0.94 | 0.18 | -6.83 | -2.30 | 0.20 | 0.37 |
| Up Capture | 234% | -283% | -277% | -25% | 33% | 3% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 12 | 20 | 26 | 60 | 116 | 322 |
| Down Capture | -18% | 106% | 413% | 245% | 148% | 104% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 10 | 22 | 37 | 66 | 130 | 359 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CALC | |
|---|---|---|---|---|
| CALC | -64.9% | 134.3% | 0.12 | - |
| Sector ETF (XLV) | 12.3% | 16.8% | 0.52 | 7.9% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | 3.2% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | -2.3% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | -0.7% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 10.1% |
| Bitcoin (BTCUSD) | -4.3% | 43.7% | 0.02 | 10.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CALC | |
|---|---|---|---|---|
| CALC | -62.8% | 101.3% | -0.49 | - |
| Sector ETF (XLV) | 6.3% | 14.6% | 0.25 | 6.2% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 7.4% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | 1.4% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | 3.9% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 11.6% |
| Bitcoin (BTCUSD) | 4.3% | 56.5% | 0.30 | 6.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CALC | |
|---|---|---|---|---|
| CALC | -45.2% | 106.2% | -0.50 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 5.6% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 7.0% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | 0.4% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 2.6% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 11.5% |
| Bitcoin (BTCUSD) | 67.6% | 66.9% | 1.07 | 5.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/3/2026 | 14.4% | 44.2% | 6.5% |
| 11/12/2025 | 4.0% | -4.4% | 34.9% |
| 8/12/2025 | -10.1% | 6.6% | 26.4% |
| 3/27/2025 | 4.0% | -7.0% | -24.6% |
| 10/30/2024 | -22.9% | -27.1% | -28.1% |
| 8/12/2024 | -3.6% | -10.3% | -5.8% |
| 5/13/2024 | 6.7% | 3.8% | -2.7% |
| 1/22/2024 | 7.1% | 16.5% | -8.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 8 | 7 |
| # Negative | 8 | 10 | 11 |
| Median Positive | 4.3% | 7.7% | 13.0% |
| Median Negative | -3.3% | -4.4% | -8.8% |
| Max Positive | 14.4% | 67.9% | 82.8% |
| Max Negative | -22.9% | -47.9% | -63.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2026 Cash Runway | |||||||
| 2027 IND Submission | |||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Roberts, Eric W | CHIEF BUSINESS OFFICER | FMTC Custodian - Roth IRA FBO Eric W. Roberts | Buy | 9222025 | 3.07 | 2,500 | 7,675 | 258,340 | Form |
| 2 | Roberts, Eric W | CHIEF BUSINESS OFFICER | FMTC Custodian - Roth IRA FBO Eric W. Roberts | Buy | 9172025 | 2.68 | 3,400 | 9,105 | 218,651 | Form |
| 3 | Roberts, Eric W | CHIEF BUSINESS OFFICER | FMTC Custodian - Roth IRA FBO Eric W. Roberts | Buy | 9152025 | 3.12 | 5,000 | 15,600 | 244,140 | Form |
| 4 | Roberts, Eric W | CHIEF BUSINESS OFFICER | FMTC Custodian - Roth IRA FBO Eric W. Roberts | Buy | 9102025 | 3.15 | 2,343 | 7,378 | 230,650 | Form |
| 5 | Roberts, Eric W | CHIEF BUSINESS OFFICER | FMTC Custodian - Roth IRA FBO Eric W. Roberts | Buy | 9022025 | 2.86 | 9,200 | 26,340 | 200,716 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.